Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisBrian G. Feagan, Asit Parikh, Paul Rutgeerts et al.|New England Journal of Medicine|2013Cited by 2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseWilliam J. Sandborn, Asit Parikh, Brian G. Feagan et al.|New England Journal of Medicine|2013Cited by 2.7k
The safety of vedolizumab for ulcerative colitis and Crohn's diseaseJean‐Frédéric Colombel, Brian G. Feagan, Edward V. Loftus et al.|Gut|2016Cited by 810
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment FailedBruce E. Sands, Stephen B. Hanauer, Brian G. Feagan et al.|Gastroenterology|2014Cited by 714
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Clinical Pharmacokinetics|2017Cited by 158